**Supplementary Table 1**. HA-CDI and CA-CDI rates for COVID-19 pre-pandemic and pandemic periods, Canadian Nosocomial Infection Surveillance Program, Canada

|  |  |  |  |
| --- | --- | --- | --- |
|  | Pre-pandemic (January 2019-February 2020) | COVID-19 pandemic (March 2020-June 2021) |  |
| Variable | Cases | Denominator | Unadjusted rate (95% CI)\*  | Cases | Denominator | Unadjusted rate (95% CI)\* | Rate change, *p-*value |
| HA-CDI  | 2856 | 8475872 patient days | 3.4 (3.3-3.5) | 3062 | 8694620patient days | 3.5 (3.4-3.7) | 4.5%, 0.0896 |
| CA-CDI | 1076 | 901923 patient admissions | 1.2 (1.1-1.3) | 1360 | 938607patient admissions | 1.5 (1.4-1.5) | 21.8%,<0.0001 |

\* HA-CDI rates were presented as 10,000 patient days and CA-CDI rates as 1,000 patient admissions

**Supplemental Table 2.** CDI patient characteristics with and without COVID-19 for 2021 cases.

|  |  |  |
| --- | --- | --- |
|  | COVID-19 patients (n=64) | non-COVID-19 patients (n=1,180) |
| Age in years, median (IQR) | 69 (54.5–79.5) | 67.5 (52–78) |
| Female sex, n (%) | 35 (54.7) | 589 (49.9) |
| Healthcare-associated CDI, n (%) | 50 (78.1) | 772 (66.1) |
| Days to CDI positive test from admission (IQR) | 10.5 (2.0–23.0) | 4.0 (1.0–13.0) |
| Temp °C, median (IQR) \* | 36.9 (36.6–37.3) | 37.0 (36.6–37.5) |
| Leukocyte count, x109/L, median (IQR)\* | 9.9 (6.3–11.5) | 9.5 (6.3–15.4) |
| Albumin, g/L, median (IQR)\* | 30.0 (26.0–34.0) | 29.0 (24.0–34.0) |
| Colectomy, n (%)\* | 1/28 (3.6) | 5/430 (1.2) |
| ICU, n (%)\* | 3/29 (10.3) | 35/435 (6.7) |
| Mortality, n (%)\* | 3/29 (10.3) | 37/432 (8.6) |

\*Clinical and outcome data were collected in March and April only as per the CNISP CDI protocol; IQR=interquartile range